Summary: A Finland-based lab has adopted Proscia’s AI-powered digital pathology software to enhance pathologists’ ability to deliver more precise and efficient cancer diagnoses.
Takeaways:
- Fimlab’s use of Proscia’s software will help pathologists leverage AI to generate more consistent interpretations of cancer cases.
- Digital pathology is evolving from efficiency-driven adoption to becoming a tool for unlocking precision medicine insights through AI.
- Proscia’s scalable platform offers a broad range of AI applications, enabling Fimlab to be at the forefront of AI-powered pathology advancements.
Fimlab Laboratories, a Finland-based provider of laboratory services, research, and training, announced it will use Proscia’s digital pathology software platform to help its pathologists generate more precise results with artificial intelligence (AI).
Growing Impact of Digital Pathology
Digital pathology is driving a shift to data-rich images, each containing billions of pixels that provide one of the most detailed and direct profiles of diseases like cancer. While laboratories initially adopted digital pathology to drive efficiency gains, they are now realizing added value by leveraging AI to unlock insights from this data that advance precision medicine.
“Artificial intelligence is beginning to solve many of pathology’s biggest challenges,” says Teemu Tolonen, MD, PhD, chief physician of Fimlab’s pathology department. “We carefully evaluated multiple software platforms and are confident Proscia’s will enable us to achieve a great impact from AI. Its open approach ensures we can leverage a broad variety of applications in our routine operations.”
Further reading: Proscia Makes Major Update to Concentriq AP
How Proscia’s Solution Will Support Fimlab
With its intuitive user experience, robust functionality, and scalability, Proscia’s software can drive all aspects of Fimlab’s daily work. Pathologists will use the platform’s AI-enabled workflows to make more consistent interpretations of the most common types of cancer and drive efficiency. This includes running applications from Proscia’s growing precision medicine AI portfolio.
“Fimlab is one of the most innovative laboratories in the world,” says David West, Proscia’s CEO. “Its team is now advancing to the forefront of AI-enabled pathology with our software, and we are incredibly excited to see the impact of our work together.”
Photo: Prosica
